BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Biotech Beach

  Janux Therapeutics to Present at Upcoming March Investor Conferences

  Janux Therapeutics, Inc. today announced that Janux management will participate in three upcoming investor conferences.

  March 1, 2022

   · 

  2 min read
• Business

  Ashvattha Therapeutics Announces Key Executive Appointments in Clinical Operations and Manufacturing

  Ashvattha Therapeutics today announced key executive appointments in clinical operations and manufacturing. Steve Carlos joins the company as Vice President, Manufacturing and Bella Oguno as Vice President, Clinical Operations.

  March 1, 2022

   · 

  3 min read
• Business

  Thermo Fisher Scientific Continues Collaboration to Support Biopharmaceutical Discovery and Development

  Thermo Fisher Scientific Continues Collaboration to Support Biopharmaceutical Discovery and Development.

  March 1, 2022

   · 

  3 min read
• Business

  Element Biosciences Partners with Interpretation Expert Genoox to Validate the AVITI™ System for the RUGD Application

  Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, today announced a partnership with Genoox, a community-driven genomic data platform, to demonstrate the clinical potential of the AVITI system for rare and undiagnosed disease research, using whole genome sequencing.

  March 1, 2022

   · 

  3 min read
• BioForest

  Alpine Immune Sciences Announces Participation in March 2022 Investor Conferences

  Alpine Immune Sciences, Inc., a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, announced that members of its management team will participate at the following investor conferences in March 2022.

  March 1, 2022

   · 

  1 min read
• Business

  Establishment Labs Reports Fourth Quarter and Full Year 2021 Financial Results; Record Fourth Quarter Revenue of $35.3 Million

  Establishment Labs Holdings Inc. announced its financial results for the fourth quarter and full year ended December 31, 2021 and provided initial 2022 guidance.

  March 1, 2022

   · 

  11 min read
• Business

  Janux Therapeutics Appoints Byron Robinson, Ph.D., J.D., as Chief Strategy Officer

  Janux Therapeutics, Inc. today announced the appointment of Byron Robinson, Ph.D., J.D., as Chief Strategy Officer.

  March 1, 2022

   · 

  5 min read
• Business

  Ray Therapeutics and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership

  Ray Therapeutics and Forge Biologics, announced a manufacturing partnership that will advance Ray Therapeutics’ lead optogenetics gene therapy program, Ray-001, into clinical trials for patients with retinitis pigmentosa.

  March 1, 2022

   · 

  4 min read
• Genetown

  Quantabio Launches Ultra-Fast RNA Library Prep Kit with Integrated Ribosomal RNA and Globin Depletion for Precision Oncology Applications

  Quantabio today announced the commercial availability of the sparQ RNA-Seq HMR Kit , an ultra-fast RNA next-generation sequencing (NGS).

  March 1, 2022

   · 

  4 min read
• Business

  IQVIA selected to accelerate clinical development of VYVGART™ (efgartigimod alfa fcab) by argenx SE

  IQVIA selected to accelerate clinical development of VYVGART™ (efgartigimod alfa fcab) by argenx SE.

  March 1, 2022

   · 

  2 min read